On Brink of Phase III, Sophiris Files IPO to Advance BPH Bid
By Randy Osborne
Staff Writer
Staff Writer
Tuesday, February 19, 2013
Aiming to start pivotal trials with its therapy for benign prostatic hyperplasia (BPH) before the end of the year, Sophiris Bio Inc. (formerly Protox Therapeutics Inc.) filed for an initial public offering (IPO) that specifies neither the number of shares nor the price range.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.